Get started
Author

Daniele Rizzi

Observed name: D. Rizzi
OpenAlex ID: A5020635495
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
2015 · N. Normanno, A.M. Rachiglio, et al. · Annals of Oncology · 148
PDF
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
2014 · F. Ciardiello, N. Normanno, et al. · Annals of Oncology · 116
PDF
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
2017 · N. Normanno, R. Esposito Abate, et al. · Annals of Oncology · 114
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
2016 · F. Ciardiello, N. Normanno, et al. · Annals of Oncology · 94
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
2018 · Sabino De Placido, Ciro Gallo, et al. · The Lancet Oncology · 90
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
2019 · Giulia Martini, Claudia Cardone, et al. · Molecular Cancer Therapeutics · 89
Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial
2014 · Domenico Galetta, Saverio Cinieri, et al. · Clinical Lung Cancer · 68
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)
2020 · Laura Orlando, Vito Lorusso, et al. · The Breast · 21
PDF
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM 2802)
2020 · Evaristo Maiello, Gabriele Di Maggio, et al. · Clinical Colorectal Cancer · 16
PDF
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
2016 · E. Martinelli, C. Cardone, et al. · ESMO Open · 11
PDF
LBA-09 Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab
2015 · F. Ciardiello, N. Normanno, et al. · Annals of Oncology · 10
Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial
2016 · E. Maiello, E. Martinelli, et al. · Annals of Oncology · 9
First-line pemetrexed plus cisplatin followed by maintenance pemetrexed versus carboplatin-paclitaxel plus bevacizumab followed by maintenance bevacizumab (ERACLE) in advanced nonsquamous NSCLC: A quality-of-life-oriented, multicenter randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale).
2013 · Domenico Galetta, Salvatore Pisconti, et al. · Journal of Clinical Oncology · 5
AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
2018 · C. Cardone, B. Blauensteiner, et al. · Annals of Oncology · 4
Sorafenib plus cisplatin and gemcitabine in the treatment of advanced hepatocellular carcinoma (HCC): A phase II study by the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2705).
2011 · F. Giuliani, A. Febbraro, et al. · Journal of Clinical Oncology · 4
Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).
2018 · Evaristo Maiello, Gabriele Di Maggio, et al. · Journal of Clinical Oncology · 3
4 Sorafenib Plus Cisplatin and Gemcitabine in the Treatment of Advanced Hepatocellular Carcinoma (hcc): a Phase Ii Study by the Gruppo Oncologico Dell'italia Meridionale (prot. Goim 2705)
2010 · F. Giuliani, R. Addeo, et al. · Cancer Treatment Reviews · 3
Impact of cabazitaxel on metastatic bone health in patients with castration resistant prostate cancer previously treated with docetaxel: CaBone Study.
2018 · Daniele Santini, Franco Morelli, et al. · Journal of Clinical Oncology · 2
When less is better: Safety and efficacy of combination of trastuzumab and continuous low oral dose chemotherapy (HEX) as first-line therapy for HER2-positive advanced breast cancer (ABC)—First early results from a phase II trial on behalf of Gruppo Oncologico Italia Meridionale (GOIM).
2013 · Laura Orlando, Francesco Giotta, et al. · Journal of Clinical Oncology · 2
AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
2019 · C. Cardone, B. Blauensteiner, et al. · Annals of Oncology · 1
PDF
Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial
2017 · C. Cardone, M.C. Paul, et al. · Annals of Oncology · 1
PDF
Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the CAPRI GOIM clinical trial
2017 · N. Normanno, R. Esposito Abate, et al. · Annals of Oncology · 1
PDF
Supplementary Figure 1 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
2023 · Giulia Martini, Claudia Cardone, et al.
Supplementary Table 1 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
2023 · Giulia Martini, Claudia Cardone, et al.
Supplementary Figure 2 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
2023 · Giulia Martini, Claudia Cardone, et al.
PDF
Works count: 37
Citation count: 812
H-index: 10
I10-index: 11
Year
Topic
Type